Spotfire R/ST Panel Mini gets special 510(k) clearance
June 27, 2024—BioMérieux announced that its Biofire Spotfire Respiratory/Sore Throat (R/ST) Panel Mini has received FDA special 510(k) clearance and CLIA waiver.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Proscia, Nucleai to broaden access to AI predictive biomarkers
June 26, 2024—Proscia has partnered with Nucleai, a spatial artificial intelligence biomarker company that maps protein expression and cellular interactions within tissue samples to predict therapeutic outcomes.
Horiba launches Yumizen H550 range with ESR and CBC/diff
June 25, 2024—Horiba announced that it has expanded its compact hematology instrument range with the launch of three models now with erythrocyte sedimentation rate onboard.
Risant acquires Cone Health
June 24, 2024—Cone Health and Risant Health have signed a definitive agreement under which Cone Health will become part of Risant Health, pending regulatory approvals.
FDA clears BioMérieux Vitek Reveal AST system
June 21, 2024—BioMérieux announced that its Vitek Reveal AST system has received FDA 510(k) clearance.
FDA clears Roche digital pathology solution for diagnostic use
June 18, 2024—Roche announced that its whole slide imaging system, the Roche Digital Pathology Dx, has received FDA 510(k) clearance.
Qiagen launches digital PCR assays for microbial applications
June 13, 2024—Qiagen has launched 35 wet-lab tested digital PCR microbial DNA detection assays for its digital PCR platform QIAcuity.
Bio-Rad launches GBS positive, negative run controls
June 11, 2024—Bio-Rad Laboratories has launched its Exact Diagnostics GBS positive and negative run controls.
Liaison Plex Yeast Blood Culture assay gets 510(k) clearance
June 7, 2024—Diasorin announced it has received 510(k) clearance from the FDA for the company’s Liaison Plex Yeast Blood Culture assay, the second molecular multiplexing panel on the Liaison Plex.
FDA clears Horiba Yumizen H2500 hematology analyzer
June 6, 2024—Horiba has announced that its high-throughput Yumizen H2500 hematology analyzer has received FDA 510(k) clearance and is available for sale in the United States.